Xianwei Medical

Xianwei Medical emerged from Beijing University of Aeronautics and Astronautics (BUAA) in 2022, translating over a decade of research in microsurgical robotics into commercial ophthalmic solutions. The company develops precision surgical robots for retinal procedures and treatment devices for dry eye disease, targeting applications where human hand limitations constrain surgical outcomes.

Company Overview

Founded by CEO Ma Weimin, with Professor Yang Yang of BUAA’s Intelligent Machinery Design and Control Laboratory serving as Chief Scientist, Xianwei Medical draws upon established academic foundations in microsurgical robotics. The research team’s work was recognized internationally in 2020 when their findings were included in the Handbook of Robotic and Image-Guided Surgery published by Elsevier—the only Chinese ophthalmic surgical robot research represented in that volume.

The company maintains a research-intensive profile, with over 70% of staff holding graduate degrees. Technical leadership comes from Lin Chuang as CTO, supported by approximately 10 engineering specialists focused on mechanical design, software development, and control algorithms.

Xianwei Medical secured Zhongguancun High-Tech Enterprise certification and was selected for the Beijing Municipal Science and Technology Commission’s High-Quality Development Support Project. The company also won the Startup Star Award at the 10th Dongsheng Cup International Entrepreneurship Competition in 2022.

Core Products

Ophthalmic Microsurgical Robot

The company’s primary platform has reached its third generation, designed for intraocular procedures including retinal vessel cannulation and subretinal injections. Key technical specifications include:

• Master-slave dual-arm control architecture
• Micrometer-level positioning accuracy at the end effector
• Motion scaling from 0 to 200x
• Millinewton-level force feedback
• 2.5mm diameter precision end effectors

The system employs a proprietary Remote Center of Motion (RCM) mechanism that positions the linear actuation degree of freedom away from the surgical site, reducing spatial interference with the surgeon’s field of view while minimizing end-effector mass.

As of 2024, the third-generation robot was undergoing type testing and preparation for innovative medical device application with NMPA.

Meibomian Gland Thermal Pulsation Treatment Device

Targeting meibomian gland dysfunction (MGD)—responsible for approximately 87.6% of dry eye cases in mainland China—this Class II medical device applies controlled thermal pulsation therapy. The device completed type testing submission in 2024 and was projected to receive NMPA clearance by late 2024, representing the company’s first product expected to generate revenue.

Pipeline Products

Additional programs in earlier development stages include:

• Intelligent Handheld Ophthalmic Assist Robot: A tremor-compensating device compatible with standard microsurgical instruments, providing force sensing and motion stabilization for manual ophthalmic procedures.

• Super-Microsurgical Robot: Targeting lymphaticovenular anastomosis (LVA) and other demanding microsurgical applications outside ophthalmology, with prototype development ongoing.

Technology & Innovation

Xianwei Medical has filed over 20 invention patents related to ophthalmic robotics and intelligent surgical instruments, with 15 patents granted. The research foundation includes more than 30 peer-reviewed publications in SCI and EI indexed journals.

Core technical competencies span:

• Advanced robotic mechanism design
• Precision drive systems
• Micro-force sensing technology
• AI algorithms for motion control
• Proprietary end-effector manufacturing

The company’s approach emphasizes complete in-house development from structural design through control algorithms, avoiding reliance on licensed components for core functionality.

Market Presence

Xianwei Medical collaborates with multiple prominent ophthalmology clinical centers for research and animal studies. The company’s initial commercial target focuses on private ophthalmology hospital chains, with projections indicating primary customers from this segment once regulatory clearances are obtained.

For the dry eye treatment device, the company has engaged CDMO partners for manufacturing and established framework agreements for Southeast Asian market distribution.

Key Milestones

• 2022-06: Company founded in Beijing
• 2022-08: Completed seed funding of several million RMB
• 2022-10: Strategic investment from BUAA Tianhui Incubator and Origin Capital
• 2022-12: Listed on Beijing Equity Exchange Dachuang Board
• 2023-05: Completed angel round of approximately RMB 25 million led by Redhill Capital
• 2024-06: New funding round led by Wuhan Institute of Biotechnology Baiyinghuicai Fund

Frequently Asked Questions

What type of surgeries can Xianwei Medical’s robot perform?

The ophthalmic microsurgical robot is designed for intraocular procedures including retinal vessel cannulation, subretinal injection, vitrectomy assistance, and membrane peeling. The platform targets surgeries where natural hand tremor and limited precision constrain outcomes.

Has Xianwei Medical received regulatory approval for its products?

As of late 2024, the company’s products remained in the regulatory approval process. The meibomian gland treatment device was nearest to commercialization, having completed type testing submission. The ophthalmic surgical robot was preparing for innovative medical device pathway application with NMPA.

What distinguishes Xianwei Medical from other ophthalmic robot developers?

The company claims its dual-arm robot achieves precision control and force feedback specifications, drawing from over 10 years of foundational research at BUAA. The proprietary RCM mechanism design reportedly optimizes surgical workspace while maintaining high performance.